Data Insights

Regorafenib by Bayer for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Relapsed Acute Myeloid Leukemia

Data Insights

Regorafenib by Bayer for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Refractory Acute Myeloid Leukemia

Data Insights

Regorafenib by Bayer for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Regorafenib by Bayer for Myelofibrosis: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Myelofibrosis

Data Insights

Regorafenib by Bayer for Glioblastoma Multiforme (GBM): Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Glioblastoma Multiforme (GBM)

Data Insights

Regorafenib by Bayer for Myelodysplastic Syndrome: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Myelodysplastic Syndrome

Data Insights

Regorafenib by Bayer for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Regorafenib by Bayer for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase III for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Regorafenib by Bayer for Rhabdomyosarcoma: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Rhabdomyosarcoma

Data Insights

Regorafenib by Bayer for Esophageal Cancer: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase III for Esophageal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Esophageal Cancer

Data Insights

Regorafenib by Bayer for Gastric Cancer: Likelihood of Approval

Regorafenib is under clinical development by Bayer and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Gastric Cancer